This page shows the latest olodaterol news and features for those working in and with pharma, biotech and healthcare.
Boehringer has been trying transfer patients from Spiriva to new combination Spiolto (tiotropium/olodaterol), but has reportedly been encountering payer resistance.
Privately-held Boehringer has been trying to patients from Spiriva to new combination Spiolto (tiotropium/olodaterol), with some payer resistance, but in the meantime Jardiance and Ofev have taken up the
Boehringer is hoping to migrate patients to new combination therapy Spiolto/Stiolto (tiotropium plus olodaterol) but with the asthma and COPD category becoming increasingly crowded and price-sensitive the combination is
combination therapy Spiolto/Stiolto (tiotropium plus olodaterol).
Ingelheim's Spiolto (tiotropium/olodaterol).
GSK is jostling for market share with other two-drug combinations, however, including Novartis' Ultibro (glycopyrronium/indacaterol), AstraZeneca's Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer Ingelheim's Spiolto
More from news
Approximately 3 fully matching, plus 23 partially matching documents found.
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...